MyanCor, Medtronic's wholly-owned subsidiary in Lin-gang Special Area Life Science & Tech Park, has successfully completed the clinical implantation of its cardiac pacemakers at multiple sites across China.

This signifies that the company has built a fully localized industrial chain for its globally leading cardiac rhythm management technology in Lin-gang, spanning R&D, production and clinical application.

MyanCor's production area in Lin-gang. [Photo/Shanghai Observer]

According to Adele Suttle, vice-president of CRM operations at Medtronic, the company will bring more of its cardiac sci-tech products to China. A range of advanced arrhythmia therapies, including implantable cardioverter defibrillators, will realize localized production in Lin-gang.

Medtronic is not the only global healthcare giant implementing such strategies. Boston Scientific announced in March that its single-use intravascular ultrasound catheter, OptiCross HD, had been approved by China's National Medical Products Administration and would be locally manufactured in Lin-gang.

Haleon invested 600 million yuan ($88.63 million) to build a high-end dental manufacturing base in Lin-gang the same month, while AstraZeneca announced the establishment of a cell therapy production and supply base and innovation center.

The reasons they chose Lin-gang are diverse. For example, Lin-gang's support for Medtronic goes beyond simple subsidies to a suite of tailored services, including efficient administrative approvals and streamlined customs clearance.

Institutional innovation is also a key advantage. By taking the lead in opening cell therapy-related businesses to foreign-invested enterprises, Lin-gang has created new opportunities for companies such as AstraZeneca.